Menu

Skip to content
  • Home
  • About Us
  • Services
  • Products
  • Contact Us
  • News & Events

Oncology

Patented products available for R&D use as permitted under 35 USC 271 (e)(1)
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
A
Abiraterone Acetate
Afatinib
Amifostine
Anastrozole
Ansamitocin P-3
Axitinib
Azacitidine
B
Bleomycin Sulfate
C
Cabazitaxel
Capecitabine
Carboplatin
Cisplatin
Cladribine
Cyclophosphamide
D
Dactinomycin
Dasatinib
Daunorubicin HCl
Decitabine
Degarelix acetate
Docetaxel Anhydrous
Docetaxel Trihydrate
Doxorubicin HCl
E
Epothilone B
Eribulin Mesilate
Erlotinib Base
Erlotinib HCl
Erythromycin Thiocyanate
Etoposide
Everolimus
F
Floxuridine
Fludarabine Phosphate
Fulvestrant
G
Gefitinib
Gemcitabine HCl
I
Ifosfamide
Imatinib Mesylate
Irinotecan HCl
Ixabepilone
L
Lapatinib Ditosylate
Lenalidomide
Letrozole
Lurbinectedin
M
Mercaptopurine
Methotrexate
Mitotane
N
Nilotinib
O
Olaparib
Oxaliplatin  
P
Paclitaxel
Palbociclib
Pamidronate Disodium 
Panobinostat
Pazopanib HCl
Pegaspargase
Pemetrexed Disodium
Pirarubicin
Pomalidomide
R
Rapamycin (Sirolimus)
Regorafenib
Rivaroxaban
Ruxolitinib Phosphate
S
Sorafenib Tosylate
Sunitinib
T
Talazoparib
Temsirolimus
Triapine
V
Valrubicin
Vinblastine Sulfate
Vincristine Sulfate
Vinorelbine Tartrate
Vorinostat
Z
Zoledronic Acid